HemaSphereCancer BiologyPeer-reviewed journal article
Linker histone H1-0 is a specific mediator of the repressive ETV6::RUNX1 transcriptional landscape
Vera Helena JepseniD, Andrea HäneliD, Daniel J. PicardiD, Rigveda BhaveiD, Rebecca Hasselmann, Juha MehtoneniD, Julian Schliehe‐DiecksiD, Carla‐Johanna Kath, Vithusan Suppiyar, Yash Prasad, Katerina Schaal, Jia‐Wey Tu, Nadine RücheliD, Ersen Kameri, Nan QiniD, Herui WangiD, Zhengping ZhuangiD, Rabea WageneriD, Lena Blümel, Tobias LautweiniD, Daniel Hein, David KoppsteiniD, Gesine KögleriD, Marc RemkeiD, Sanil BhatiaiD, , Ute FischeriD
Abstract
ETV6::RUNX1 is the most common oncogenic fusion in pediatric B cell precursor acute lymphoblastic leukemia (BCP-ALL). It induces a clinically silent preleukemic state that requires secondary mutations for progression to leukemia. However, the molecular mechanisms contributing to the characteristic quiescence of ETV6::RUNX1+ preleukemic cells remain elusive. Here, we detect factors involved in the preleukemic state by generating human induced pluripotent stem cell (hiPSC) models using CRISPR/Cas9 gene editing. We identified upregulation of linker histone H1-0 in our preleukemic models, which was preserved upon hematopoietic differentiation and transformation to BCP-ALL. ETV6::RUNX1 induces H1-0 promoter activity whereas depletion of H1-0 specifically inhibited ETV6::RUNX1 signature genes, indicating its role as a key mediator of the ETV6::RUNX1 transcriptome. Single-cell gene expression analysis revealed high H1-0 levels in quiescent cells during hematopoiesis and inverse correlation with transcriptional activity. Pharmacologically, H1-0 protein levels correspond to susceptibility of BCP-ALL towards histone deacetylase inhibitors (HDACi). Altogether, our study provides novel insights into ETV6::RUNX1-induced quiescence and suggests that further investigation into combinatorial treatment of BCP-ALL using the H1-0- inducing HDACi Quisinostat may be worthwhile.
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- approach: genetic perturbation / CRISPR
- Citations
- 4
- FWCI
- 2.74
- Field percentile
- top 10%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cell cycle corruption in a preleukemic ETV6-RUNX1 model exposes RUNX1 addiction as a therapeutic target in acute lymphoblastic leukemia
J. P. Wray, E. M. Deltcheva, … T. Enver·bioRxiv·Dec 22, 2020
- ETV6/RUNX1 Fusion Gene Abrogation Decreases The Oncogenic Potencial Of Tumour Cells In A Preclinical Model Of Acute Lymphoblastic Leukaemia.
A. Montano, J. L. Ordonez, … J. M. Hernandez-Rivas·bioRxiv·Oct 18, 2019
- Single cell characterization of B-lymphoid differentiation and leukemic cell states during chemotherapy in ETV6-RUNX1 positive pediatric leukemia identifies drug-targetable transcription factor activities
J. Mehtonen, S. Teppo, … M. Heinaniemi·Genome MedicinePeer-reviewed·Nov 20, 2020
- RUNX1-ETO induction rapidly alters chromatin landscape and growth of a specific sub-population of hESC-derived myeloid precursor cells by interfering with RUNX1 regulation
M. Nafria, P. Keane, … C. Bonifer·bioRxiv·Aug 28, 2019
- T505A variant of ETV5 promotes proliferation of precursor B cells in a mouse model of acute lymphoblastic leukemia
Joshua Yi, Michael P. Wu, … Rodney P. DeKoter·bioRxiv·Dec 19, 2024
- Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition
S. F. Cai, S. H. Chu, … S. A. Armstrong·bioRxiv·May 11, 2020